JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
REDWOOD CITY, Calif., Feb. 15, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilar company with late-stage clinical products, today announced that it has scheduled a conference call for Monday, February 29, 2016 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and year end 2015 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.
Financial results will be released over the wire after market close on Monday, February 29, 2016 and posted at http://investors.coherus.com.
Conference Call Information
When: Monday, February 29, 2016 at 1:30 p.m. PT
Dial-in: (765) 507-2587 (domestic) or (844) 452-6826 (toll free)
Conference ID: 52921197
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
INVESTOR AND MEDIA CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239
